Controversies in multi-institutional phase I clinical trials

Clinical Advances in Hematology and Oncology

Volumn 7, Issue 8, 2009, Pages 518-520

  Dowlati, Afshin ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CENTER; CANCER RESEARCH; CLINICAL STUDY; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG RESEARCH; EXPERIMENTAL DESIGN; HEALTH CARE ORGANIZATION; HUMAN; INTERPERSONAL COMMUNICATION; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM TOLERATED DOSE; PATIENT CARE PLANNING; RESEARCH ETHICS; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; HUMANS; MULTICENTER STUDIES AS TOPIC; NEOPLASMS; RESEARCH DESIGN;

EID: 70349678817     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (2)

1. Le Tourneau C, Lee JJ, Siu, LL. Dose Escalation Methods in Phase I Cancer Clinical Trials. J Natl Cancer Inst. 2009;101:708-720.
2. Dowlati A, Manda S, Gibbons J, Remick SC, Patrick L, Fu P. Multi-Institutional Phase I Trials of Anticancer Agents. J Clin Oncol. 2008;26:1926-1931.